Clinical Report: STOPGAP II — a national randomized clinical trial for patients with stage 4 gastric cancer

Overview

STOPGAP II is a national randomized clinical trial aimed at patients with stage 4 gastric cancer and peritoneal carcinomatosis. Building on the findings from STOPGAP I, this trial seeks to evaluate new treatment paradigms for gastric carcinomatosis.

Background

Gastric cancer is a leading cause of cancer mortality worldwide, particularly in advanced stages where treatment options are limited. The STOPGAP trials were initiated in response to the increasing incidence of advanced gastric cancer among younger patients and the need for effective treatment strategies. The findings from these trials could significantly influence the management of gastric cancer with peritoneal metastases.

Data Highlights

No numerical data available in the source material.

Key Findings

• STOPGAP II is designed to test new treatment approaches for gastric carcinomatosis.
• The trial is accruing participants ahead of expectations.
• STOPGAP I established the safety and feasibility of the treatment approach.
• Gastric cancer remains a significant health challenge, with poor outcomes in advanced stages.
• Current guidelines emphasize the importance of systemic therapy and encourage participation in clinical trials.

Clinical Implications

The STOPGAP II trial may provide insights into effective treatment strategies for patients with advanced gastric cancer. Participation in clinical trials is essential for advancing treatment options in this patient population.

Conclusion

The STOPGAP II trial represents a critical step in exploring new treatment paradigms for stage 4 gastric cancer, potentially impacting future clinical practice.

Related Resources & Content

1. Butensky, Cancer, 2025 -- Consensus guideline for the management of gastric cancer with synchronous peritoneal metastases
2. Nivolumab plus chemotherapy as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 5-year follow-up results from CheckMate 649
3. Phase III Trial Comparing Intraperitoneal and Intravenous Paclitaxel Plus S-1 Versus Cisplatin Plus S-1 in Patients With Gastric Cancer With Peritoneal Metastasis: PHOENIX-GC Trial
4. Gastric Cancer — Phase II Randomized Trial Evaluating Nimotuzumab with Irinotecan Versus Irinotecan Monotherapy as Second-Line Treatment for Advanced Gastric Cancer Patients
5. The ASCO Post — Targeted Therapy Gaining Ground in the Second-line Treatment of Gastric Cancer
6. Gastric Cancer — Evaluating Short-term Effects of Preoperative Chemotherapy Using Docetaxel, Oxaliplatin, and S-1 in Gastric Cancer with Significant Lymph Node Involvement (JCOG1704)
7. Gastric Cancer (Springer) — Long-term survival results from a phase II study of perioperative capecitabine combined with oxaliplatin in advanced gastric cancer with significant lymph node involvement: OGSG 1701
8. Consensus guideline for the management of gastric cancer with synchronous peritoneal metastases - Butensky - 2025 - Cancer - Wiley Online Library
9. Nivolumab plus chemotherapy as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 5-year follow-up results from CheckMate 649 - PubMed
10. Phase III Trial Comparing Intraperitoneal and Intravenous Paclitaxel Plus S-1 Versus Cisplatin Plus S-1 in Patients With Gastric Cancer With Peritoneal Metastasis: PHOENIX-GC Trial | Journal of Clinical Oncology